View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 10, 2022updated 11 Jul 2022 1:54pm

Denali starts subject dosing in frontotemporal dementia therapy trial

The study will evaluate DNL593’s pharmacokinetics, pharmacodynamics, tolerability, and safety in FTD-GRN patients.

Denali Therapeutics has started dosing of subjects in a Phase I/II clinical trial of DNL593 to treat frontotemporal dementia-granulin (FTD-GRN).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed by the company’s Protein Transport Vehicle (PTV) technology, DNL593 is an investigational, brain-penetrant recombinant progranulin (PGRN) replacement therapy.

Denali entered a strategic collaboration with Takeda to jointly develop and commercialise DNL593, which is intended to slow or prevent FTD-GRN progression by increasing intracellular and extracellular functional PGRN levels.

The randomised, multicentre, placebo-controlled, double-blind Phase I/II study is designed to evaluate DNL593’s pharmacokinetics, pharmacodynamics, tolerability, and safety in healthy subjects and FTD-GRN patients.

Denali Therapeutics chief medical officer Carole Ho said: “Denali has a diverse portfolio of therapeutic candidates to address neurodegenerative and lysosomal diseases, and DNL593 is our second Transport Vehicle (TV) technology-enabled programme to enter clinical development.

“Initiation of this Phase I/II trial is an important development milestone for the programme, and we look forward to continued collaboration with Takeda and the FTD community in our unified purpose to develop DNL593 as a treatment option for people and families living with FTD-GRN.”

The trial is a three-part (Parts A-C) study, and subject dosing has commenced in the single ascending dose Part A in healthy participants.

The multiple dose, 25-week Part B study will be conducted in FTD-GRN patients, and the 18-month open-label Part C study is the extension of FTD-GRN patients who participated in Part B.

FTD-GRN is characterised by a deficiency of progranulin (PGRN) in the brain. In 2019, Denali commenced patients’ dosing in a Phase Ib clinical trial of DNL151 to treat Parkinson’s disease.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena